Novartis : Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high risk node negative disease marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Drs Mayer and Kalinsky provide insights and offer their impressions of the PADA-1 trial, focusing on ESR1 mutation monitoring with circulating tumor DNA (ctDNA).
Endocrine therapy, particularly when administered in combination with Verzenio (abemaciclib), is effective when compared with chemotherapy among patients with metastatic breast cancer who experienced disease progression on Ibrance (palbociclib), according to recently published research.
The AURKA inhibitor alisertib has emerged as an agent of particular note, demonstrating early signals of efficacy with a manageable safety profile for the treatment of patients with locally advanced or metastatic breast cancer whose disease is resistant to endocrine therapies.